The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
 
Luis A Meza
No Relationships to Disclose
 
Jasnoor Malhotra
No Relationships to Disclose
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Nazli Dizman
Consulting or Advisory Role - Vivreon Biosciences
 
Joann Hsu
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Alex Chehrazi-Raffle
No Relationships to Disclose
 
Ramya Muddasani
No Relationships to Disclose
 
Ameish Govindarajan
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Tanya B. Dorff
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; AstraZeneca; Bayer; Exelixis; Janssen Oncology; Pfizer; Seagen
Research Funding - Pfizer (Inst)
 
Yung Lyou
Consulting or Advisory Role - Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Janssen Oncology
 
Paul Henry Frankel
Stock and Other Ownership Interests - Asensus Surgical; Geron
Consulting or Advisory Role - Johnson & Johnson/Janssen
Other Relationship - FlexSim
 
Sumanta K. Pal
Consulting or Advisory Role - F. Hoffmann LaRoche; F. Hoffmann LaRoche; Roche
Research Funding - Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen